Fetal sheep defend blood pressure, blood volume, and blood gases using baro-and chemoreflexes that influence autonomic and neuroendocrine responses. The local generation of prostanoids within the fetal brain is also an important component in activating hormone responses to these stimuli, but the relationship between the reflexes and prostanoid biosynthesis is unclear. The present study was performed to test the hypothesis that the abundances of prostaglandin biosynthetic enzymes in the fetal brain are dependent upon the activity of the baro-and chemoreflex pathways. We subjected chronically catheterized fetal sheep in late gestation to a 10-minute period of brachiocephalic occlusion (BCO), a stimulus that provokes brisk cardiovascular and neuroendocrine responses. We compared the central nervous system abundance of prostaglandin endoperoxide synthases 1 and 2 (PGHS-1 and PGHS-2) after BCO to (1) fetal sheep that had been subjected to BCO after chronic sinoaortic denervation plus bilateral vagotomy and (2) fetal sheep in which the N-methyl D-aspartate (NMDA) receptor antagonist, ketamine, had been administered prior to BCO. Abundances of messenger RNA (mRNA) for PGHS-1 and of mRNA and protein for PGHS-2 in fetal hippocampus were reduced significantly by either prior denervation or ketamine administration. Prostaglandin endoperoxide synthases 1 and 2 mRNA in pituitary were decreased and increased, respectively, by ketamine pretreatment. The results of this study are consistent with the conclusion that the expression of PGHS-1 and -2 in fetal hippocampus and pituitary are influenced by the baro-and/or chemoreflex pathways within the fetal brain in late gestation.
Introduction
Fetal sheep respond to hypoxia, 1-3 hypotension, 4,5 and hypovolemia 6, 7 with increases in circulating concentrations of adrenocorticotropin (ACTH), vasopressin (AVP), and cortisol via activation of the hypothalamic-pituitary-adrenal (HPA) axis. This neuroendocrine activation is mediated by changes in afferent neural activity of arterial baro-and chemoreceptors of the carotid sinus as well as central nervous system (CNS) chemosensation. 4 The specific population of receptors responsible for mediating the reflex response is dependent upon the nature of the stimulus (ie, ventilatory hypoxia vs hypotension vs hypovolemia). Our studies indicate that the local biosynthesis of prostanoids within the fetal brain is also important in generating hormone responses to these stimuli. Pretreatment of fetal sheep with indomethacin, an inhibitor of both isoforms of prostaglandin endoperoxide synthase (PGHS, cyclooxygenase), attenuated ACTH and AVP secretion in acute hypotension. 5 This action was more pronounced in intact than in sinoaortic denervated fetuses, 5 suggesting that intact baro-and chemoreflexes influence prostanoid production or activity during the response.
Both PGHS-1 and -2 are widely expressed within the fetal brain. 8, 9 Prostaglandin endoperoxide synthase 2 is upregulated by a variety of factors, including hormones, 10 growth factors, 11 neuronal activity, 12 and cerebral ischemia. 13 Prostaglandin endoperoxide synthase 1 is considered a constitutively expressed enzyme 14 ; however, its expression may be altered under certain physiological circumstances. 15 We have demonstrated that cerebral hypoperfusion upregulates the expression of both PGHS isoforms in the fetal sheep brain although PGHS-1 is less readily upregulated than PGHS-2. 16 Increased expression of PGHS isoforms after stimulation of cardiovascular reflex pathways, combined with the observation that blockade of fetal CNS prostaglandin biosynthesis reduces reflex responsiveness to hypotension or cerebral hypoperfusion, led us to hypothesize that increased activity along baroand chemoreflex pathways during hypotension is necessary for the upregulation of PGHS enzyme expression in the fetal sheep brain. Reflex activity of these pathways was blocked using 2 methods (1) physical interruption of afferent projections by sinoaortic denervation of carotid sinus and vagus nerves and (2) pharmacologic inhibition of central glutamatergic pathways with the anesthetic ketamine. Ketamine acts within the brain as a noncompetitive N-methyl D-aspartate (NMDA) receptor inhibitor. 17, 18 It is known that the central integration of the baroand chemoreflexes are, in part, mediated by NMDA-sensitive excitatory synapses in several brain regions including the brain stem 19, 20 and hypothalamus. 21, 22 Therefore, blockade of these pathways interrupts the chemoreflex in the fetus. 23 
Materials and Methods
These experiments were approved by the University of Florida Animal Care and Use Committee and were performed in accordance with the Guiding Principles for Use of Animals of the American Physiological Society.
We studied 18 fetal sheep of mixed western breeds (10 singleton and 10 twin pregnancies) that were between 123 and 136 days (term ¼ 148) at the time of experimentation. Fetuses from singleton and twin pregnancies were included in each group. The first experimental group comprised fetuses that were instrumented but not subjected to brachiocephalic occlusion ([BCO] no BCO, n ¼ 7). The second experimental group of fetuses was subjected to BCO alone (n ¼ 7). The third group consisted of fetuses that were subjected to BCO and had undergone sinoaortic denervation and bilateral vagotomy at the time of initial catheterization (denervated, n ¼ 6). The final group of fetuses was treated with ketamine (10 mg, intravenous [iv], Phoenix Pharmaceuticals, St Joseph, Missouri) exactly 10 min prior to BCO, as previously described 24 (ketamine, n ¼ 4).
Fetal Surgery
Fetal surgery was performed as previously described. 24 Briefly, polyvinylchloride catheters (0.030 in inner diameter [id], 0.050 in outer diameter [od], Saint Gobain Performance Plastics, North Clearwater, FL) were inserted into each tibial artery and the tip advanced to the subdiaphramatic aorta. Catheters (0.040 in id, 0.070 in od) were also inserted into the saphenous veins bilaterally. After closure of the skin incision, the amniotic fluid was catheterized using a polyvinylchloride catheter (0.050 in id, 0.090 in od) sutured to the skin of one hind limb. After exposure of the fetal head through a second hysterotomy incision, both lingual arteries were exposed and catheterized (0.030 id, 0.050 in od) and the tips advanced retrogradely into the common carotid arteries. In fetuses subjected to peripheral baro-and chemodenervation, the common carotid arteries and vagosympathetic trunks were identified and exposed on both sides. Carotid sinus denervation and bilateral vagotomy were performed according to a method similar to that previously described. 25 Finally, an extravascular balloon occluder (8 mm diameter; In Vivo Metric Healdsburg, California) was placed around the brachiocephalic artery. All ewes were treated with ampicillin (750 mg, subcutaneous) and rectal temperatures and food consumption were recorded twice a day for 5 days following the surgery. The ewes were monitored for fever, anorexia, lethargy, and other signs of infection or distress.
In Vivo Experimental Procedures
During experiments, femoral and lingual arterial and amniotic fluid pressures were measured using an online data acquisition system (Labview version 6.01, National Instruments, Austin, Texas) for 35 minutes. One-minute averages of fetal heart rate and vascular and amniotic pressures were calculated from the phasic pressures. Brachiocephalic occlusion was initiated by maximal inflation of the occluder with 2 mL saline for 10 minutes. Hemodynamic data from the BCO and ketamine groups have been reported previously. 24 In a pilot experiment in which we measured gene expression 0.5, 3, 8, and 18 hours after the onset of BCO, we found that gene expression responses to BCO were greatest at 3 hours. The data from this pilot experiment are not reported because of the small number of animals per group (n ¼ 3, resulting in low statistical power). Therefore, ewes and fetuses were humanely euthanized 3 hours after the onset of BCO. The fetus was immediately delivered by cesarean section and the brain regions (medulla, hypothalamus, frontal cortex, cerebellum, hippocampus, and pituitary) were isolated in an RNAse-free environment, immediately frozen in liquid nitrogen, and stored at À80 C for later analysis of PGHS-1 and -2 messenger RNA (mRNA) abundance.
RNA Isolation and Real-Time PCR Quantification
RNA was isolated using Trizol (Invitrogen, Carlsbad, California) according to the manufacturer's recommendations as previously described. 26 Each pellet was resuspended in 160 mL RNAsecure (Ambion, Austin, Texas), and incubated at 60 C for 10 minutes to inactivate RNAse activity. Four 40 mL aliquots were made for each sample and stored at À80 C. The absorbance of each sample at 260 nm and 280 nm was read by a spectrophotometer (Bio-Tek Corp, Winooski, Vermont) to determine RNA concentration and purity.
Sets of oligonucleotide primers and FAM/TAMRA probes for PGHS-1, PGHS-2, and ribosomal RNA (rRNA) were designed, optimized, and validated for efficiency. 26 Sequences have been reported previously. 26 Each sample was assayed by real-time quantitative polymerase chain reaction (RT-qPCR) in triplicate, 25 mL total volume 1-step RT-PCR reactions using a Prism 7000 Sequence Detection (Applied Biosystems, Foster City, California) as previously described. 22 Relative mRNA expression of each gene was calculated by determining change in threshold cycle (C t ) between the mean C t for each gene and the mean C t for rRNA from the same sample.
Protein Isolation and Western Blot
Protein from cortex, cerebellum, and hippocampus were isolated from the collected tissues by homogenizing *0.1 g pulverized tissue in 750 mL of hot lysis buffer consisting of 1% (w/v) sodium dodecyl sulfate (SDS), 1.0 mmol/L sodium orthovanadate, and 10 mmol/L Tris pH 7.4 using a polytron homogenizer. Homogenates were suspended in boiling water for 5 minutes, cooled for 2 minutes. Protease inhibitor cocktail (Sigma-Aldrich Corp, St Louis, Missouri) was added and each sample was placed on ice. Each homogenate was spun at 7500g for 10 minutes at 4 C to pellet the cellular debris. A small volume of supernatant was removed for protein quantification using the DC Protein Assay (BioRad, Hercules, California) and the remainder aliquoted and stored at À80 C until analyzed. Brain stem tissue and pituitary were not successfully analyzed for PGHS-1 and -2 protein.
Microsomes were isolated from fetal hypothalami using a protocol adapted from Glazner et al. 27 Hypothalami were pulverized and 0.1 to 0.2 mg tissues were homogenized in sucrose ethylenediaminetetraacetic acid (EDTA) buffer (pH 7.4, 1 mmol/L EDTA, 0.32 mol/L sucrose, 0.1 mmol/L dithiothreitol (DTT), 1 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES]) with a Potter-Elvehjem tissue grinder (Kimble/Kontes, Vineland, New Jersey). Protease inhibitor cocktail (Sigma-Aldrich Corp) was added to prevent protein degradation. Homogenates were centrifuged for 500g for 10 minutes at 4 C. The supernatant was transferred to thickwalled, polyallomer ultracentrifuge tubes (#355642; Beckman Coulter, Palo Alto, California), filled with ice-cold homogenization buffer and spun at 16 500 rpm (10 000g) for 20 minutes in a L90K ultracentrifuge (Beckman Coulter). The resulting supernatant was transferred to a new ultracentrifuge tube and spun at 36 800 rpm (100 000g) for 1 hour at 4 C. The pelleted microsomes were resuspended in approximately 100 mL of homogenization buffer, assayed using the DC Protein Assay (BioRad), and stored at À80 C until analyzed.
Microsome samples were diluted Biosciences, Piscataway, New Jersey) or sheep anti-mouse IgG (NA 931; Amersham Biosciences) secondary antibody for 1 hour at room temperature. All antibodies were diluted in blocking buffer. After washing 3 times for 10 minutes in PBST, membranes were visualized using enhanced chemiluminescence (ECL Plus, Amersham Biosciences) and developed for 30 minutes (PGHS-1) or 5 minutes (PGHS-2) on film. Band optical densities were quantified using Quantity One software (BioRad).
Calculations and Statistics
Data are presented as mean values + standard error (SE). Data were analyzed by 2-way analysis of variance (ANOVA) corrected for repeated measures in one dimension (time) and, if significant, by pairwise contrasts. 28 Statistics were performed using SPSS version 17 for Windows (SPSS Inc, Chicago, Illinois).
Results
Fetal blood gases at the start of the experiment were within our laboratory range for normoxic fetuses ( Table 1 ). The denervated fetuses had somewhat lower values of PaO 2 compared to the other groups. This is consistent with the impaired ability of denervated fetuses to defend blood pressure and blood gases. 29 Fetal femoral and lingual blood pressures and fetal heart rate responses to BCO are shown in Figure 1 . The magnitude of change in fetal lingual arterial blood pressure was not statistically significantly different among the 3 experimental groups. The intensity of stimulus was therefore equal in the 3 groups subjected to BCO. Blood pressure and heart rate data for 2 of these groups (BCO and ketamine; Figure 1 ) have been reported previously. 24 The abundances of PGHS-1 and -2 mRNA were significantly related to the specific brain region studied, with the highest levels of PGHS-1 in cortex and pituitary and of PGHS-2 in the cerebral cortex and hippocampus (P < .001 by ANOVA for both PGHS-1 and -2). Abundances of PGHS-1 and -2 mRNA (all regions) and protein (hypothalamus, hippocampus, cortex, and cerebellum) are reported in Figures 2 and 3 . Analysis of PGHS-1 in the 4 groups by 2-way ANOVA revealed a significant treatment effect (P ¼ .015; Figure 2 ). Analysis of PGHS-2 mRNA levels by 2-way ANOVA revealed a main effect of group (P ¼ .01) and group Â region interaction (P ¼ .009). Pretreatment with sinaortic denervation plus bilateral vagotomy or ketamine significantly reduced hippocampal PGHS-1 mRNA and PGHS-2 mRNA and protein abundances (Figure 2 , top panels) compared to intact BCO-treated and control (No BCO) fetuses (P < .05 by pairwise contrast). Ketamine reduced the PGHS-1 mRNA and increased PGHS-2 mRNA abundance in pituitary (P < .001 and P ¼ .001 by ANOVA, respectively, and P < .05 for both PGHS-1 and -2 by pairwise contrast; Figure 4 , upper panels). None of the treatments significantly altered mRNA abundances for PGHS-1 or -2 in the brain stem (Figure 4 , lower panels).
Discussion
The results of the present study are consistent with the concept that levels of PGHS-1 and -2 mRNA in the fetal hippocampus and PGHS-2 mRNA in hypothalamus are dependent upon the activity of the fetal baroreflex and/or chemoreflex pathways. The results suggest that both PGHS forms are influenced both by the stimulus itself and by the activity of the reflex pathways that respond to the stimulus. The mRNA levels of PGHS-1 and -2 are higher in hippocampus than in other brain regions, and this pattern of expression is at least in part the result of chemoreflex pathway activity. The generation of prostaglandins by PGHS enzymes within the fetal brain is important in augmenting the fetal reflex responses to acute hypotension. 5 We have previously reported that expression of PGHS enzymes increases following BCO in specific regions of the brain, especially in medullary brain stem, hypothalamus, and hippocampus. [30] [31] [32] We have also reported 31 an increase in local tissue concentrations of prostaglandin E 2 (PGE 2 ). In our original experiments aimed at investigating the upregulation of PGHS isoforms in response to cerebral hypoperfusion, we used a rather more severe cumulative stimulus, a 10-minute BCO in acutely prepared and anesthetized fetuses. [30] [31] [32] In a subsequent study, we used conscious, chronically instrumented fetal sheep that had been subjected to a 10-minute BCO and found that the upregulation of PGHS-2 1 hour after BCO was less dramatic, yet statistically significant in medullary brain stem. 16 We were unable to reliably reproduce this upregulation in medullary brain stem in the present study[AQ: The citation of Table 3 has been deleted as it is not significant. Please check.]. In choosing the 3-hour time point for measuring gene expression for PGHS-1 and -2, we have focused the present study on the more chronic influences on the expression of these genes. Interestingly, the negative effect of ketamine and denervation was apparent in hippocampus. We have consistently found that the level of expression of PGHS in late gestation fetal sheep is highest in hippocampus and cerebral cortex 33 ; perhaps it should not be surprising that a manipulation that reduces expression would be best observed in structures with the highest expression levels.
It is possible that the abundance of PGHS-2 in the fetal hippocampus and cerebral cortex is in part dependent upon the neurotransmission that results from activity of impinging pathways. If this is indeed true, the reduction in PGHS-2 mRNA abundance in hippocampus by ketamine or denervation reflects reduced influence of baroreceptor and/or chemoreceptor activity on the hippocampus. Prostaglandin endoperoxide synthase 2 is known to be upregulated by neuronal activation in physiological and pathological states. Natural synaptic activity regulates basal levels of the enzyme, while high-frequency synaptic activity produced by seizure or long-term potentiation (LTP) paradigms rapidly induces PGHS-2 expression. 12, 34 Following seizure PGHS-2 immunoreactivity is present in distal dendrites and dendritic spines, structures involved in synaptic signaling. 34 Using other noncompetitive inhibitors, Yamagata et al 12 demonstrated that PGHS-2 was upregulated by excitatory activity via the NMDA receptor, a glutamate receptor subtype. MK-801, one such noncompetitive inhibitor, downregulated basal levels of PGHS-2 mRNA in the hippocampus and cortex. 12 The role of the hippocampus in the neuroendocrine control mechanisms in the late gestation fetus is not clear. The observations that (1) ketamine blocks the fetal ACTH response to BCO; (2) brain regional concentrations of PGE 2 correlate with PGHS-2 (but not PGHS-1) mRNA concentrations; and (3) intracerebroventricular injection of PGE 2 stimulates robust fetal ACTH secretion suggest that there might be a causeand-effect relationship between hippocampal function and fetal ACTH secretion. In adult rats, binding of corticosterone to both glucocorticoid and mineralocorticoid receptors inhibits ACTH secretion via an effect on the paraventricular nucleus. 35 Hippocampal-limbic interactions are also known to influence ACTH responsiveness to stress. 36 In the fetus, on the other hand, there have been few studies aimed at understanding the role of the hippocampus in the control of fetal ACTH. In what has perhaps been the only such study, McDonald and coworkers 37 reported that fornix lesions (which should sever the pathways between the hippocampus and the paraventricular nucleus) did not alter unstressed fetal ACTH or cortisol concentrations or alter the timing of parturition (which in sheep is dependent upon spontaneous increases in fetal HPA axis activity at the end of gestation). Understanding the importance-or lack thereof-of the hippocampus in fetal neuroendocrine control will require studies more specifically aimed at understanding the hippocampal function.
While the present results are consistent with the conclusion that treatment of the fetus with ketamine effectively inhibited the upregulation of PGHS-2 mRNA following BCO via blockade of NMDA receptors, ketamine is known to possess antiinflammatory actions through other mechanisms. In a model of lipopolysaccharide (LPS) injury in the liver, ketamine attenuated PGHS-2 protein expression and nuclear factor kappa B (NF-kB)-binding activity. 38 Ketamine also reduced LPSinduced PGE 2 production in primary glial cell cultures not thought to express NMDA receptors. 39 In the present study, cellular hypoxia caused by BCO may have stimulated transcription factors such as NF-kB; therefore, we cannot rule out the possibility that ketamine interactions with these factors may have contributed to the inhibition of PGHS-2 mRNA levels.
The manipulation of PGHS-1 mRNA abundance following BCO and either denervation or ketamine injection is an interesting and perhaps surprising finding. Historically, PGHS-1 has been labeled a ''housekeeping'' enzyme that is constitutively expressed in many tissues. 14 Few studies have reported PGHS-1 to be inducible; however in vitro research has shown that PGHS-1 is transcriptionally upregulated by retinoic acid and glucocorticoids in neuroblastoma cell lines 40 and by histone deacetylase inhibitors in astrocytes. 41 Gene induction may involve the coordinate functioning of an SP-1 site in the promoter and an AP-1 site in an intron. 42 While PGHS-1 and -2 expressions are sometimes apparently concomitantly changed (eg, in hippocampus), these 2 genes are clearly not identically regulated (eg, in hypothalamus). A more detailed analysis of the cell types within each brain region will be helpful in understanding the role of each of these enzymes in reflex control mechanisms. While we do know that only a small proportion of the PGHS-1 and -2 expressions is in vasculature, we do not know, for example, whether one isoform is biased toward neurons and the other toward glia. We cannot yet define the anatomical relationship between PGHS-1 and -2 and the NMDA-glutamatergic pathways that are known to mediate baro-and chemoreflex controls. We have identified cell populations within the fetal brain that increase PGHS-1 and/or -2 expression in response to BCO in anesthetized and acutely prepared fetuses (eg, CA1, CA3, and dentate gyrus regions of the fetal hippocampus), 32 and we have identified specific nuclei in medulla, hypothalamus, and other regions that increase Fos expression in response to BCO in chronically prepared fetuses. 43 But we do not yet know which specific nuclei contain cells that express both NMDA receptors and PGHS-2. This information will be helpful for understanding the basis of the PGHS-reflex interactions in the fetal brain.
We conclude that the activity of NMDA-dependent glutamatergic pathways, including (but not necessarily limited to) pathways important for mediating the neuroendocrine responses to reduced cerebral perfusion pressure, is an important determinant of PGHS-2 mRNA levels in the fetal brain. We conclude that this influence of glutamatergic neuronal activity is most clearly observed in the hippocampus, a brain region with high levels of PGHS-2 mRNA. The results suggest the possibility that the hippocampus expresses PGHS-2 in late gestation in part as a result of vigorous glutamatergic input to this region in the final weeks of fetal development in utero.
